Incomplete PRN Narcotic Pain Documentation
Summary
The facility failed to ensure pain assessments were completed before and after the administration of PRN narcotic pain medications for four sampled residents: R4, R8, R16, and R18. Facility policies for Pain Management and PRN Medication required use of a pain assessment tool appropriate to the resident’s cognitive status, documentation of the reason for PRN use, the time of administration, and evaluation of effectiveness. The policies also stated that pain management would be reassessed at established intervals for effectiveness and adverse consequences. R18 was admitted with diagnoses including cerebral infarction, neuralgia, and unspecified pain, and her care plan included pain-related interventions and opioid-related goals. Her MAR showed documented administrations of Hydrocodone-Acetaminophen with pain assessments before and after administration, but the Medication Monitoring/Control Record showed additional tablets removed that were not documented on the MAR. For March 2026, 17 tablets were removed and 13 PRN doses were missing from the MAR, including pain assessment and reevaluation. For April 2026, 10 tablets were removed and 8 PRN doses were missing from the MAR, also without the required pain assessment and reevaluation. R4 was admitted with diagnoses including diastolic heart failure, wedge compression fracture of T11-T12 vertebra, and unspecified pain. Her care plan identified pain related to age, decreased mobility, restless leg syndrome, muscle spasms, and opioid use. Her MAR showed one documented Tramadol administration in March 2026, one in April 2026, and none in May 2026, while the Medication Monitoring/Control Record showed 9 tablets removed in March, 6 in April, and 7 in May. In each month, multiple PRN doses were missing from the MAR, including pain assessments and reevaluations before and after administration. R16 was admitted with cerebrovascular disease, Alzheimer’s disease with late onset, and idiopathic neuropathy. Her care plan addressed pain related to hip fracture history, decreased range of motion, arthritis, weakness, CVA, and muscle weakness. Her MAR showed no documented Hydrocodone-Acetaminophen administrations in April 2026 and one documented administration in May 2026, while the Medication Monitoring/Control Record showed 5 tablets removed in April and 9 in May. In both months, PRN doses were missing from the MAR, including pain assessment and reevaluation. R8 was admitted with Type 2 diabetes mellitus with hyperglycemia, unspecified myalgia, and acquired absence of the left foot and right great toe. Her care plan addressed acute pain related to toe amputation and opioid use. Her MAR showed no documented Hydrocodone-Acetaminophen administrations in March 2026, four documented administrations in April 2026, and none in May 2026, while the Medication Monitoring/Control Record showed 5 tablets removed in March, 16 in April, and 7 in May. In each month, PRN doses were missing from the MAR, including pain assessments and reevaluations before and after administration.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.